PerkinElmer Life Sciences

Genetix CloneSelect Imager Can Replace MTT Assay for Cytotoxicity

Date Posted: Thursday, July 29, 2010

Print Email to a friend

Genetix announces the availability of an independent, peer-reviewed publication comparing cytotoxicity testing using its CloneSelect Imager™ system against widely-used, colorimetric MTT assay. The work was performed at the Leiden Institute of Chemistry, Leiden University and published in BioMed Central Biotechnology.

Entitled ‘Accurate non-invasive image-based cytotoxicity assays for cultured cells’, the paper concludes: “This new image-based technique has the potential to replace the cumbersome MTT assay when fast, unbiased and high-throughput cytotoxicity determination is required.”

Charles de Rohan, head of the Genetix Business Unit within Leica Microsystems, added, “Apart from the advantages of speed and ease of use, the label-free, non-destructive imaging technique used by the CloneSelect Imager system offers the unique possibility to directly analyze cell proliferation and cell death as a function of time, thereby revealing the effect of potential cytotoxic agents and generating a dose response curve.”

CloneSelect Imager provides a non-invasive, image-based alternative to MTT assays. As no staining is required the use of colorimetric kits is avoided, saving both time and cost. Using white light imaging and advanced image analysis, the system is used to track cell growth in each well of a microplate, determining cell confluence and estimating cell number. Data can be displayed visually and exported for further analysis.

For more information please visit:

• BMC Biotechnology: http://www.biomedcentral.com/content/pdf/1472-6750-10-43.pdf

• CloneSelect Imager: http://www.genetix.com/en/systems/cloneselectimager/introduction/index.html.

Further Information: http://www.genetix.com



Related Products

Genetix Launches new CytoGenetix Reagents and Kits
Genetix’s new range of reagents, CytoGenetix, will be sold alongside its CytoVision® workstations.

Genetix Launches new CytoGenetix Reagents and Kits
Genetix’s new range of reagents, CytoGenetix, will be sold alongside its CytoVision® workstations.



Related news from our archive

Genetix Pharmaceuticals Announces Global Clinical Plans to Treat Adrenoleukodystrophy
Gene therapy technology licensed from National Institute of Health and Medical Research (INSERM) featured in November issue of science.

Genetix Announces Further Expansion into Digital Pathology Market through Acquisition of SlidePath
Genetix acquires all of the issued share capital of SlidePath, in order to strengthen its position in the digital pathology market.

Genetix Group plc Awarded Scottish NHS Cytogenetics Contract
Over 70 CytoVision® workstations to provide an automated solution for Scotland’s entire network of cytogenetic laboratories.

Genetix Pharmaceuticals Announces Global Clinical Plans to Treat Adrenoleukodystrophy
Gene therapy technology licensed from National Institute of Health and Medical Research (INSERM) featured in November issue of science.

Genetix Announces Further Expansion into Digital Pathology Market through Acquisition of SlidePath
Genetix acquires all of the issued share capital of SlidePath, in order to strengthen its position in the digital pathology market.

Genetix Group plc Awarded Scottish NHS Cytogenetics Contract
Over 70 CytoVision® workstations to provide an automated solution for Scotland’s entire network of cytogenetic laboratories.

  
Select Biosciences Ltd